



European Federation of Pharmaceutical  
Industries and Associations




# Immuno-Oncology – New Ways Of Tackling Cancer

Nathan Vastesaegeer , MD, PhD

23 May 2018

Lead Oncology Medical Affairs MSD Europe, Africa, Middle-East




**“Unlocking  
Tomorrow’s Cures”**





# CANCER TREATMENT – WHERE WE ARE TODAY

## In The Past Two Decades We Have Made Major Progress In Treating Cancer




\* - Changes in 5-year relative survival (%) for the most common cancers, all stages, all ages, SEER 9\*, 1975-2012  
Source: Jemal A et al. (2017), Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival; JNCI J Natl Cancer Inst 109(9)

Today, 7 out of 10 patients with Non-Hodgkin Lymphoma live at least 5 years. In the mid-70's it was less than half.

# IMMUNO-ONCOLOGY – THE BASICS

## CANCER IMMUNITY CYCLE



## IMMUNO-ONCOLOGY APPROACHES<sup>2</sup>

1.

**Monoclonal antibodies**  
Man-made versions designed to target and boost the specific cells that will stop the cancer.

2.

**Cancer vaccines**  
Substances introduced into the body to cause an immune response against certain diseases.

3.

**Non-specific immunotherapies**  
Treatments that boost the immune system generally, which can help it attack cancer cells.

## PATIENT ACCESS

# Differences In Approvals By FDA & EMA

75% of the new drugs approved by both the FDA and the EMA between 2006 and 2010 were first approved in the U.S.<sup>1</sup>

What's more, the FDA approved 32 of 35 prospective cancer drugs from 2003 to 2010 – only 26 were approved by the EMA.<sup>2</sup>

23 of these drugs were approved by both the FDA and EMA – FDA approved 91% first.<sup>2</sup>



ALL 23 drugs came to the U.S. market before the European market.<sup>2</sup>

# Patient Access Solutions Across Europe



Germany grants immediate access & allows for bundling of indications.



France and the UK have specific access schemes in place such as ATU and EAMS, respectively



Italy has created an Innovation Fund to incentivise access to innovative cancer medicines



Belgium, Denmark and The Netherlands have created so-called Multi-Year-Multi-Indication Agreements to accelerate access to the various indications of the latest Immuno-Oncology medicines



Sources: <sup>1</sup> FDA: Is the US really slower than Europe at approving new drugs? Accessed March 11, 2012. Available: <http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM247470.pdf>

<sup>2</sup> Roberts SA, Allen JD, Sigal EV. Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe. Health Affairs, June 2011.

THANK YOU!

Q&A

UNLOCKING  
TOMORROW'S  
CURES

efpia